New drug targets for genomic cancer therapy: Successes, limitations, opportunities and future challenges

Current Cancer Drug Targets

Volumn 1, Issue 1, 2001, Pages 33-47

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE;

ANIMAL; DRUG DESIGN; DRUG SCREENING; FORECASTING; GENE EXPRESSION PROFILING; GENE THERAPY; GENETICS; GENOME; HUMAN; METHODOLOGY; NEOPLASM; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FORECASTING; GENE EXPRESSION PROFILING; GENE THERAPY; GENOME, HUMAN; HUMANS; NEOPLASMS;

EID: 0035342306     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009013334269     Document Type: Article

References (82)

1. Hanahan, D.; Weinberg, A. The Hallmarks of Cancer. Cell 2000, 700, 57-70.
2. International Human Genome Sequencing Consortium. Natitrel 2001, 409, 860-921
3. Venter, J. C.; et al. The Sequence of the Human Genome. Science 2001,297, 1304-1351.
4. Brent, R. Genomic Biology. Cell 2000, 700, 169183.
5. Jiminez-Sanchez, G.; Childs, B.; Valle, D. Human Disease Genes. Nature 2001, 409, 853-855.
6. Garret, M. D.; Workman, P. Millennium Review. Discovering Novel Chemotherapeutic Drugs for the Third Millennium. Eur. J. Cancer 1999, 35, 2010-2030.
7. Workman, P. Towards Genomic Cancer Pharmacology: Innovative Drugs for the New Millennium. Curr. Opin. Oncol. Endocr. Metabol. Invest. Drugs 2000, 2, 21-25.
8. Workman, P. Towards Intelligent Anticancer Drug Screening in the Post-Genome Era? Anti-Cancer Drug Design 1997,72, 525-531.
9. Kaelin, W. G. Choosing Anti-Cancer Drug Targets in the Postgenomic Era. J. Clin. Invest. 1999, 704, 1503-1506.
10. Gibbs, J. B. Mechanism-Based Target Identification and Drug Discovery in Cancer Research. Science 2000,257, 1969-1973:
11. Strohman, R. C. Genomics and Human Life Span What's Left to Extend? Nature Biotech. 2001, 19, 195.
12. World Health Report. Life in the 21st Century. A Vision for All. World Health Organisation, 1998.
13. Sikora, K.; Advani, S.; Koroltchouk, V.; Magrath, I.; Levy, L.; Pinedo, H.; Schwartsmann, G.; Tattesall, M.; Van, S. Essential Drugs for Cancer Therapy: A World Health Organisation Consultation. Annal. Oncol. 1999, 70, 385-390.
14. Bonney, R. The Complete Guide to Cancer, 2nd Edition. PJB Publications Ltd, Richmond, Surrey, 1998.
15. [ 15] Scrip Magazine, Issue 95, February 2001, pp 68-70.
16. Gelmon, K. A.; Eisenhauer, E. A.; Harris, A. L.; Ratain, M. J.; Workman, P. Anticancer Agents Targeting Signalling Molecules and Cancer Cell Environment: Challenges for Drug Development. J. Nail. Cancer Inst. 1999,97, 1281-1287.
17. Goldenberg", M. M. Trastuzumab, a Recombinant DNA-Derived Humanised Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer. Clin. Ther. 1999,21, 309-318.
18. Shak, S. Overview of the Trastuzumab (Herceptin) Anti-HER2 Monoclonal Antibody Clinical Programme in HER-2 Overexpressing Metastatic Breast Cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 1999,26, 71-77.
19. [19 ] Workman, P. Emerging Molecular Therapies: SmallMolecular Drugs In Principles of Molecular Oncology; Bronchud, M. H.; Foote, M. A.; Peters, W. P.; Robinson, M. O., Eds; Humana Press: Totowa, NJ, 2000, pp 421-437.
20. Waters, J. S.; Webb, A.; Cunningham, D.; Clarke, P. A.; Raynaud, F.; di Stefano, F.; Cotter, E. Phase I clinical and pharmacokinetic study of Be 1-2 antisense oligonucleotide therapy in patients with nonHodgkins lymphoma. J. Clin. Oncol. 2000,18, 1812 -1823.
21. Habib, E. N. (Ed) Cancer Gene Therapy: Past Achievements and Future Challenges in Experimental Medicine and Biology. Kluwer: New York, 2000.
22. Springer, C. J.; Niculescu-Duvaz, I. ProdrugActivating Systems in Suicide Gene Therapy. J. Clin. Invest. 2000, 705, 1161-1167.
23. Marais, R. M.; Spooner, R. A.; Light, Y.; Martin, J.; Springer, C. J. Extracellular Expression of the Carboxypeptidase G2 Enzyme for Activation of a Mustard Prodrug in Gene-Directed Enzyme Therapy. Nature Biotech. 1997,15, 1373-1377.
24. Jain, R. K. Delivery of Novel Therapeutic Agents in Tumours: Physiological Barriers and Strategies. J. . Natl. Cancer Inst. 1989, 81, 570 - 576.
25. Gibbs, J. B.; Oliff, A. Pharmaceutical Research in Molecular Oncology. Cell, 1994, 79, 193 - 198.
26. Monks, A.; Scudiero, D. A.; Johnson, G. S.; Paull, K. D.; Sausville, E. A. The NCI Anti-Cancer Drug Screen: A Smart Screen to Identify Effectors of Novel Targets. Anti-Cancer Drug Design 1997,12, 533 541.
27. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. I.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubenstein, L. V.; Anderson, N. L.; Buolamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Dunow, B.; Viswanadhan, V, N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An Information Intensive Approach to the Molecular Pharmacology of Cancer. Science 1997,275, 343-349.
28. Fitzsimmons, S.; Workman, P. W.; Grever, M.; Paull, K.; Camelier, R.; Lewis, A. D. Reductase Expression Across the National Cancer Institute Tumour Cell Line Panel: Correlation with Sensitivity to Mitomycin C and EO9. J. Natl. Cancer Inst. 1996, 88, 259-269.
29. Wosikowski, K.; Schuurhuis, D.; Johnson, K.; Paull, K. D.; Myers, T.; Weinstein, J. N.; Bates, S. Identification of Epidermal Growth Factor Receptor and c-erbB2 Pathway Inhibitors by Correlation with Gene Expression Patterns. J. Natl. Cancer Inst. 1997,59, 1505-1515.
30. Scherf, U.; Ross, D. T.; Waltham, M.; Smith, L. H.; Lee, J. K.; Tanabe, L.; Kohn, K. W.; Reinhold, W. C.; Myers, T. G.; Andrews, D. T.; Scudiero, D. A.; Eisen, M. B.; Sausville, E. A.; Pommier, Y.; Botstein, D.; Brown, P. O.; Weinstein, J. N. A Gene Expression Database for the Molecular Pharmacology of Cancer. Nature Genet. 2000, 24, 227 - 235.
31. Clarke, P. A.; Hostein, L; Banerji, U.; Di Stefano, F.; Maloney, A.; Wallon, M.; Judson, I.; Workman, P. Gene Expression Profiling of Human Colon Cancer Cells Following Inhibition of Signal Transduction by 17-Allylamino-17-demethoxygeldanamycin, an Inhibitor of the Hsp90 Molecular Chaperone. Oncogene 2000,19, 4125- 4133.
32. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Workman, P. DT-Diaphorase Expression and Tumour Cell Sensitivity to 17-Allylamino-17demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90. J. Natl. Cancer Inst. 1999, 91, 22, 19401949.
33. Sharp, S. Y.; Kelland, L. R.; Valenti, M. R.; Brunton, L. A.; Hobbs, S.; Workman, P. Establishment of an Isogenic Human Colon Tumour Model for NQO1 Gene Expression: Application to Investigate the Role of DT-Diaphorase in Bioreductive Drug Activation In Vitro and In Vivo. Mol. PharmacoL, 2000, 58, 1146-1155.
34. Rodrigues, A. K. Preclinical Drug Metabolism in the Age of High Throughput Screening: An Industrial Perspective. Pharmaceutical Res. 1997,14, 1505-1515.
35. Raynaud, F. I.; Goddard, P.; Fischer, P.; McClue, S.; Workman, P. Cassette Dosing Pharmacokinetics for 107 Analogues of the Trisubstituted Purine CDK2 Inhibitor Roscovitine. Proc. Am. Soc. Cancer Res. 2001, Abstr. #2056, p382.
36. Bevan P, Ryder,H, Shaw I. Identifying Small Molecule Lead Compounds: The Screening Approach to Drug Discovery. Trends Biotechnol. 1995,13, 115 -121.
37. Aheme, W.; Garrett, M.; McDonald, T.; Workman, P. Mechanism-Based High Throughput Screening for Novel Anticancer Drug Discovery. In press.
38. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in a Drug Discovery and Development Setting. Adv. Drug Deliv. Revs. 1997,23, 3-25.
39. Rishton, G. M. Reactive Compounds and in vitro False Positives in HTS. Drug Discovery Today 1997, 2, 49 - 58.
40. Floyd, C.; Le Blanc, C.; Whittaker, M. Combinatorial Chemistry as a Tool for Drug Discovery. Prog. Med. Client. 1999,36, 91-167.
41. Li, G.; Guo, T. ECLiPS Technology for Drug Discovery. In Frontiers of Biotechnology and Pharmaceutical. Zhao K, Reiner J, Chen S-H, Eds, Volume 1, Science Press: New York, 2000, pp 150-163.
42. Leach, A. R.; Hann, M. M. The insilico World of Virtual Llibraries. Drug Discovery Today 2000, 5, 326-337.
43. Peterson, R. T.; Link, B. A.; Dow.ling, J. E.; Schreiber, S. L. Small Molelcule Developmental Screens Reveal the Logic and Timing of Vertebrate Development. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12965-12969.
44. Bishop, A. C.; Ubersax, J. A.; Petsch, D. T.; Matheos, D. P.; Gray, N. S.; Blethrow, J.; Shimizu, E.; .Tsien, J. Z.; Schultz, P. G.; Rose, M. D.; Wood, J. L.; Morgan, D. O.; Shokat, K. M. A Chemical Switch for Inhibitor-Sensitive Alleles of any Protein Kinase. Nature 2000, 407, 395-401.
45. Ling, C.; Mitchell, J. B. Functional Imaging and its Application to Radiation Oncology. Sem. Radiât. Oncol. 2000, 11.
46. Sausville, E. A. New Drugs Discovered in the Last Decade: Vacuous Hype, Future Promise, Neither or Both? ID Weekly Highlights, Current Drugs, March, 2001, 40-42.
47. Gibbs, J. Mechanism-based target identification and drug discovery in cancer research. Science 2000,257, 1969-1973.
48. Eisenhauer, E. A. From the Molecule to the Clinic Inhibiting HER2 to Treat Breast Cancer. N. EngJ. J. Med. 2001,11, 841-842.
49. Slamon, D.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Woher, J.; Pegram, M.; Baselga, J.; Norton, L. Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2. New Engl J. Med. 2001, 344, 783-792.
50. Buchdunger, E. Apoptosis-Induction by GLIVEC (STI571), A Targeted New Therapy for CML. Proc Am Assoc Cancer Res. 42, Proceedings Suppl. 2001, 9-10.
51. Druker, B. J. STI 571: A Paradigm for Clinical Trials of Molecularly Targeted Agents. Proc. Am Assoc Cancer Res. 42, Proceeding Suppl. 2001, 6264.
52. Schinder, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science 2000,289, 1938-1941.
53. Baselga, J.; Averbuch, S. D. ZD1839 ('Iressa') äs an Anticancer Agent. Drugs 2000, 60, Suppl l, 33-40.
54. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 Network. Nature 2000, 408, 307-312.
55. Komarov, P. G.; Komarov, E. A.; Kondratov, R. V.; Christov-Tselkov, K.; Coon, J. S.; Chemov, M. V.; Gudkov, A. V. A Chemical Inhibitor of p53 that Protects Mice from the Side Effects of Cancer Therapy. Science 1999,255, 1733-1737.
56. Foster, B. A.; Coffey, H. A.; Morin, M. J.; Rastinejad, F. Pharmacological Rescue of Mutant p53 Conformation and Function. Science 1999,286, 2507-2510.
57. Drews, J. Genomic Sciences and the Medicine of Tomorrow. Nature Biotech. 1996,14, 1518-1519.
58. Drews J. Drug Discovery: A Historical Perspective. Science 2000,287, 1960-1964.
59. Editorial. The Human Genome, in Proportion. Lancet 2001, 357, 489.
60. Editorial. A Cold Dose of Medicine. Nature Biotech. 2001,19, 181.
61. Fletcher, L. Curagen Sets Precedent in Post Genomics Era. Nature Biotech. 2001, 19, 186-187.
62. Claverie, J-M. What if there are only 30,000 human genes? Science 2001,297, 1255-1257.
63. Sorek, R.; Amitai, M. Piecing together the Significance of Splice. Nature Biotechh. 2001,19, 196.
64. Bailey D.; Zanders E.; Dean P. The end of the beginning for genomic medicine. Nature Biotech 2001,19, 207-209.
65. Peltonel L, McKusick V A. Dissecting human disease in the postgenomic era. Science 2001, 297, 1224-1229.
66. Futreal, P. A.; Ksprzyk, A.; Birney E, Mullikin J C, Wooster R, Stratton M R. Cancer and genomics. Nature 2001, 409, 850-855.
67. Editorial. All hands on deck at dawn. Nature Genetics 2001, 27, 347-349.
68. Interview with A. Oilman. Molecular Interventions 2001, 7, 14-21.
69. McMahon, M.; Woods, D. Regulation of the p53 pathway by Ras, the plot thickens. Biochem. Biophys. Acta 2001, 7477, M63-M71.
70. van Berkum, N. L.; Holstege, F. C. P. DNA microarrays: Raising the profile. Ciirr. Opin. Bioteclmol. 2001, 72, 48-52.
71. Lockhart, D. J.; Winzelar, E. A. Genomics, gene expression and DNA arrays. Nature 2000, 405, 827836.
72. Debouck, C.; Goodfellow, P. N. DNA microarrays in drug discovery and development. Nature Genet. 1999,27,48-51.
73. Stratowa, C.; Wilgenbus, K. K. Gene expression profiling in drug discovery. Curr. Opin. Mol. Ther. 1999, 7, 671-679.
74. Page, M. J.; Amess, B.; RohlfT, C.; Stubberfield, C.; Parekh, R. Proteomics: A major new technology for the drug discovery process. Drug Discovery Today 1999, 4, 55-62.
75. Hahn, W. C.; Counter, C. M.; Lundberg, A. S.; Bijersbergen, R. L.; Brooks, M. W.; Weinberg, R. A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400, 464-468.
76. Vogelstein, B.; Kinzler, K. The multistep nature of cancer. Trends Genet. 1993, 9, 138-141.
77. Hartwell, L.; Stankase, P.; Roberts, C.; Murray, A.; Friend, S. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 275, 1064-1068.
78. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Kinzler, K. W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P-4; Discafan, C. Combinatorial chemoprevention of intestinal neoplasia. Nature Med. 2000, 9, 1024-8.
79. Evans, W. E.; Relling, M. V. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999,286,487-491.
80. Ratain, M. J.; Nelling M. V. Gazing into crystal ball - Cancer-therapy in the post- genomic era. Nature Med. 2001, 7, 283-285.
81. Anon. Personalised medicine worries big pharma. Scrip No 2592. November 15th 2000, p 16.
82. Gwyne, P.; Heebner G. Technologies in cancer research: progress at the molecular level. Science 2001,291, 2035-2262.